US grants emergency approval to Lilly Covid-19 antibodies

Washington (AFP) – The US Food and Drug Administration on Monday granted emergency approval to a synthetic antibody treatment against Covid-19 developed by Eli Lilly, after the drug was shown to reduce the risk of hospitalization and emergency room visits.Bamlanivimab at a dose of 700 milligrams was authorized for the treatment of mild-to-moderate Covid-19 in adults and children aged 12 years and older who are at high risk for progressing to the severe form of the disease.It is the first major drug to be approved that was designed specifically against the new coronavirus.”As illustrated by tod…

Read More

HEDGE accordingly